iShares MSCI Hong Kong ETF vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? iShares MSCI Hong Kong ETF trades at $22.1 (market cap $1.16B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.74 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 21.8× iShares MSCI Hong Kong ETF's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while iShares MSCI Hong Kong ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Hong Kong ETF for 61 Days and Royalty Pharma plc Class A Ordinary Shares for 0 Days on average.
| EWH | RPRX | |
|---|---|---|
Market Cap | $1.16B | $25.27B |
Volume | 3,176,523 | 3,671,183 |
Sector | Broad Market / Factor | Health |
52-Week High | $24.55 | $63.96 |
52-Week Low | $20.66 | $35.44 |
Typical Hold Time | 61 Days | 0 Days |
Enterprise Value | — | $32.50B |
Dividend Yield | — | 1.66% |
Signals from Pluang's Aura AI — not financial advice
EWH, the iShares MSCI Hong Kong ETF, trades at $21.58, down 0.19% today amid bearish technical signals with moving averages indicating strong selling pressure. The ETF tracks Hong Kong equities, which have faced volatility due to Federal Reserve policy and US-Iran tensions, as reflected in recent Hang Seng Index declines. Key support sits at $21 with resistance clustered around $22. Financial ratios are unavailable in the current dataset.
Outlook remains cautious given bearish technicals and macroeconomic headwinds impacting Hong Kong markets. Opportunities exist if geopolitical tensions ease and technology stocks rebound, but risks include prolonged Fed tightening and China economic struggles. Investors should monitor Hang Seng Index momentum and institutional flow trends for directional cues.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →